氰美马嗪

氰美马嗪用途

Cyamemazine 是一种抗精神病药,其中含有吩噻嗪发色团,通常被用作抗焦虑药。Cyamemazine 是具有抗精神病活性的有效的 5-HT3 (Ki 为 12 nM), 5-HT2A (Ki 为 1.5 nM) 和 5-HT2C (Ki 为 75 nM) 受体拮抗剂。

氰美马嗪名称

[ CAS 号 ]:
3546-03-0

[ 中文名 ]:
氰美马嗪

[ 英文名 ]:
Cyamemazine

[英文别名 ]:

Kyamepromazin
Kyamepromazine
7204 R.E.
Ciamatil
Cyamemazine
Tercian

氰美马嗪生物活性

[ 描述 ]:

[ 相关类别 ]:

研究领域 >> 神经疾病

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体

信号通路 >> 神经信号通路 >> 5-HT受体

[ 靶点 ]

5-HT2A Receptor:1.5 nM (Ki)

5-HT2C Receptor:12 nM (Ki)

5-HT3 Receptor:75 nM (Ki)

[体外研究]

Cyamemazine对多巴胺受体有很高的亲和力,这与它的抗精神病活性是一致的。Cyamemazine对毒蕈碱受体的拮抗活性与其对M1(Ki=13nm)、M2(Ki=42nm)、M3(Ki=321nm)、M4(Ki=12nm)和M5(Ki=35nm)受体的亲和力一致[1]。

[体内研究]

在离体豚鼠回肠5-HT3依赖性收缩和大鼠心动过缓反应中,在大鼠脑膜5-HT2C依赖性磷脂酶C刺激中,在离体大鼠主动脉环和离体豚鼠气管5-HT2A依赖性收缩中,Cyamemazine作为5-HT3、5-HT2C和5-HT2A受体的拮抗剂。CyimeMa嗪拮抗5-HT3和5-HT2C受体,并且这种效应部分地参与了其在焦虑症中的治疗活性。急性给药小剂量的Cyamemazine可降低大鼠纹状体细胞外多巴胺和代谢物浓度[1]。

[参考文献]

[1]. Bourin M, et al. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev. 2004 Fall;10(3):219-29.

[2]. Vendrell-Criado V, et al. Photobehavior of the antipsychotic drug cyamemazine in a supramolecular gel protective environment. J Photochem Photobiol B. 2020 Jan;202:111686.

氰美马嗪物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
479.0±45.0 °C at 760 mmHg

[ 分子式 ]:
C₁₉H₂₁N₃S

[ 分子量 ]:
323.455

[ 闪点 ]:
243.5±28.7 °C

[ 精确质量 ]:
323.145630

[ PSA ]:
55.57000

[ LogP ]:
4.62

[ 蒸汽压 ]:
0.0±1.2 mmHg at 25°C

[ 折射率 ]:
1.655

[ 储存条件 ]:
2-8°C，密封，干燥

氰美马嗪MSDS

详细MSDS(安全技术说明书)

氰美马嗪毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: SN6950000

CHEMICAL NAME :: Phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)-

CAS REGISTRY NUMBER :: 3546-03-0

BEILSTEIN REFERENCE NO. :: 0093261

LAST UPDATED :: 199703

DATA ITEMS CITED :: 3

MOLECULAR FORMULA :: C19-H21-N3-S

MOLECULAR WEIGHT :: 323.49

WISWESSER LINE NOTATION :: T C666 BN ISJ B1Y1&1N1&1 ECN

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: Standard Draize test

ROUTE OF EXPOSURE :: Administration into the eye

SPECIES OBSERVED :: Rodent - rabbit

REFERENCE :: FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982- Volume(issue)/page/year: 20,573,1982

TYPE OF TEST :: Rinsed with water

ROUTE OF EXPOSURE :: Administration into the eye

SPECIES OBSERVED :: Rodent - rabbit

REFERENCE :: FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982- Volume(issue)/page/year: 20,573,1982 ** ACUTE TOXICITY DATA **

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 107 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JATOD3 Journal of Analytical Toxicology. (Preston Pub. Inc., POB 48312, Niles, IL 60648) V.1- 1977- Volume(issue)/page/year: 17,386,1993

氰美马嗪安全信息

[ 符号 ]:

GHS09

[ 信号词 ]:
Warning

[ 危害声明 ]:
H410

[ 警示性声明 ]:
P273-P501

[ 危害码 (欧洲) ]:
Xi

[ 危险品运输编码 ]:
UN 3077 9 / PGIII

[ 海关编码 ]:
2934300000

氰美马嗪合成路线

详细合成路线

氰美马嗪上下游产品

氰美马嗪上游产品

氰美马嗪下游产品

氰美马嗪海关

[ 海关编码 ]: 2934300000

[ 中文概述 ]:
2934300000. 含一个吩噻嗪环系的化合物(吩噻嗪环系不论是否氢化,化合物未经进一步稠合的 ). 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2934300000. other compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

氰美马嗪文献

Identification and quantification of 35 psychotropic drugs and metabolites in hair by LC-MS/MS: application in forensic toxicology.

Int. J. Legal Med. 129(2) , 259-68, (2015)

Despite a non-invasive sampling, hair samples are generally collected in limited amounts for an obvious esthetic reason. In order to reduce the required quantity of samples, a multianalytes method all...

Fatal intoxication with milnacipran

J. Forensic Leg. Med. 15(6) , 388-90, (2008)

The antidepressant milnacipran is a double serotonin/noradrenalin reuptake inhibitor. The low reported incidence of intoxication indicates excellent tolerance in comparison with tricyclic and second g...

Prise en charge médicamenteuse de l’anxiété chez le patient souffrant de schizophrénie

Encephale 37 Suppl 1 , S83-9, (2011)

L’anxiété est un symptôme fréquent et majeur de la schizophrénie. Elle est un symptôme clinique dominant dans la phase prodromique [indice de progression vers la « décompensation psychotique »] et acc...

更多文献